You searched for "BCG"

113 results found

Recent developments in bladder cancer

There have been some exciting developments in bladder cancer over the last few years. Immunotherapy has prolonged survival in a proportion of patients with metastatic disease, with sustained efficacy in some. Advances in genetic analysis and molecular subtyping make personalised...

Recent developments in bladder cancer – NMIBC

Every year, roughly 10,300 individuals are diagnosed with bladder cancer in the UK, making it the 11th most common cancer in the UK, and the eighth most common cancer in men [1]. Of those diagnosed with the disease, 75-85% will...

Upper tract urothelial carcinoma following cystectomy

Metachronous upper tract urothelial cancer (UTUC) is encountered in about 5% of patients after radical cystectomy (RC) with a median time to diagnosis of 24-36 months after RC, and most are asymptomatic and detected by surveillance protocols. In this multivariate...

Testosterone supplementation after prostatectomy – journey from bad to good

The role of androgens in the pathogenesis of prostate cancer is quite complex and is not entirely clear yet. Despite several reports suggesting testosterone use is safe in patients diagnosed with prostate cancer, many clinicians are still reluctant to use...

All biochemical recurrences are equal, but some are more equal than others

Despite significant technological advancements, radical prostatectomy (RP) and radiotherapy (RT) are not always effective in curing localised prostate cancer (PCa). Many patients experience a rise in prostate-specific antigen (PSA), known as biochemical recurrence (BCR), leading to considerable anxiety and a...

Artificial intelligence in bladder cancer diagnostics

Bladder cancer (BCa), ranking as the 10th most common cancer worldwide, poses a significant health burden with high morbidity and mortality [1]. Timely tumour detection and accurate evaluation are crucial for effective management, as the prognosis is dependent on the...

An algorithm for the management of haemorrhagic cystitis

Haemorrhagic cystitis (HC) can be one of the most difficult conditions to treat in urological practice. It is characterised by intractable bleeding from the bladder and may be acute or chronic. The most frequently reported causal factors are radiotherapy (RT)...

Characteristics of APC and the usefulness of MP-MRI for diagnosis

The authors evaluated the pathological and oncological characteristics of anteriorly located prostate cancer (APC) in 728 RP specimens, and the accuracy of multiparametric magnetic resonance imaging (MP-MRI) for APC evaluation. Patients were characterised as APC (70% or more of tumour...

HOLEP and detrusor underactivity

Lower urinary tract symptoms (LUTS) are common among adult males, significantly influence quality of life (QoL) and contribute to pressure on the NHS. LUTS are conventionally associated with benign prostatic obstruction (BPO), which is commonly observed during the histological progression...

Near-infrared fluorescence in robotic surgery

This is a systematic review and critical analysis of the current evidence on the applications of near-infrared fluorescence (NIRF) in robotic urologic surgery. It uses indocyanine green (ICG), a sterile water-soluble dye which has been tested in various fields. In...

Urinary biomarkers for surveillance of non-muscle invasive bladder cancer

Bladder cancer (BC) is the ninth most common cancer worldwide with a yearly incidence of approximately 430,000 cases. There is a male predominance and it is the seventh most common cancer in men worldwide [1]. Non-muscle invasive bladder cancer (NMIBC)...

Challenges of upper tract urothelial carcinoma

Upper tract uroepithelial carcinoma (UTUC) is a fairly common disease which traditionally had poorer outcomes compared to bladder cancer. This is due to various factors leading to delayed diagnosis and problems in risk stratification. Continuing efforts have focused on early...